Non-invasive diagnostics company, RSP Systems, has completed the second closing of its Series B funding round, bringing in an additional €3.85 million and increasing the total of the round to €10.35 million.
Euros
The monies raised will be used to fund clinical trials and to prepare for regulatory approval and market launch in Europe.
Both existing and new investors have contributed to the funding round. Among the new investors is TRUMPF Venture, the corporate venture arm of the TRUMPF Group — machine tools and lasers specialist.
“We are grateful for the loyal support of existing shareholders and are excited to have attracted new and equally savvy shareholders in this second closing,” said RSP System’s CEO, Andreas Jenne. “The participation of TRUMPF Venture points to the fact that we are on track towards sourcing, production, and commercialization; the timing of this could not have been better.”
“We are very happy to be part of the RSP support team,” remarked Dr Dieter Kraft, managing director of TRUMPF Venture. “RSP Systems is expected to be the breakthrough innovator the medical industry has waited decades for. For TRUMPF the investment allows insights to new application areas of photonic systems where we can bring additional value based on our knowledge.”